Esophagogastric Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Esophagogastric Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma [Phase 1, Phase 2]
Platform Phase 1/2 trial evaluating neoadjuvant regimens containing trastuzumab deruxtecan for HER2-positive, resectable esophagogastric ade…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma [Phase 2]
Phase 2 clinical trial update evaluating TNT with FLOT chemotherapy and durvalumab, followed by postoperative durvalumab, for resectable eso…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer [Phase 1]
A Phase 1 clinical trial update describing mesothelin-targeted CAR T-cell therapy in esophagogastric and mesothelin-expressing tumors, curre…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma [Phase 3]
A Phase 3 trial compares the combination of trifluridine/tipiracil plus fruquintinib versus trifluridine/tipiracil alone in metastatic esoph…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma [Phase 1, Phase 2]
This update reports the completion of a Phase 1/2 clinical trial evaluating sacituzumab govitecan for metastatic esophagogastric adenocarcin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. [Phase 2]
Phase 2 trial evaluating pre-operative nivolumab and ipilimumab followed by postoperative nivolumab in localized MSI/dMMR esophagogastric ad…
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab, trastuzumab, and the FLOT regimen as perioperative therapy for localized HER2-positive esop…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma
A clinical trial exploring hypoxia-driven metabolic response in esophagogastric adenocarcinoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-25Clinical Trial Update: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma [Phase 2]
A Phase 2 study of Telomelysin (OBP-301) in combination with pembrolizumab for esophagogastric adenocarcinoma has completed and posted resul…
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: Nintedanib in Patients With Advanced Esophagogastric Cancer [Phase 2]
Phase 2 trial update of nintedanib in advanced esophagogastric cancer.
-
CLINICAL_TRIALS research · 2018-07-06Clinical Trial Update: Could a Preoperative Feeding Jejunostomy Decrease Sarcopenia for Patients With Oesogastric Adenocarcinoma ?
An update on a trial investigating whether a preoperative feeding jejunostomy can reduce sarcopenia in patients with esophagogastric adenoca…
-
CLINICAL_TRIALS withdrawal · 2017-05-09Clinical Trial Update: Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) [Phase 2]
A Phase 2 trial of nintedanib plus mFOLFOX6 for previously untreated metastatic esophagogastric adenocarcinoma has been withdrawn.